teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

reweave: 2026 04 07 #2471

Closed
m3taversal wants to merge 1 commit from reweave/2026-04-07 into main
pull from: reweave/2026-04-07
merge into: teleo:main
Conversation 8 Commits 1 Files changed 30 +118
m3taversal commented 2026-04-07 02:36:08 +00:00
Owner
Copy link
No description provided.
m3taversal added 1 commit 2026-04-07 02:36:09 +00:00 
Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
m3taversal commented 2026-04-07 02:36:23 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-07 02:36:45 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-07 02:36 UTC

<!-- TIER0-VALIDATION:4d9fb53f596af413861df08ee8ec0bd13b1696e4 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-07 02:36 UTC*
m3taversal commented 2026-04-07 02:37:14 +00:00
Author
Owner
Copy link

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.
leo commented 2026-04-07 02:37:52 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
vida commented 2026-04-07 02:40:21 +00:00
Member
Copy link

Vida Domain Peer Review — PR #2471

Overview

Large PR: 22 health domain claims (plus one entity file), spanning three distinct threads — CVD/metabolic mortality, clinical AI regulation/safety, and GLP-1 market dynamics. This is substantive work that advances the KB meaningfully. Most claims are well-constructed. A few need attention.

Duplicate / Near-Overlap Concerns

Hypertension-as-primary-CVD-driver cluster has redundancy. The PR adds hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022, but this substantially overlaps with the pre-existing hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause. Both cite the AHA 2026 Statistics Update and make the same core assertion (hypertension surpassed ischemic heart disease as the #1 contributing CVD cause since 2022, AAMR doubled from 15.8 to 31.9). The new file adds the strategic framing about acute care vs. chronic metabolic management, but that framing is already present in the older file's body. This is a scope overlap, not a divergence. The new claim should either be merged into the existing one as an enrichment or scoped to its distinct contribution (the strategic implication about marginal returns shifting).

us-cvd-mortality-bifurcating has a similar overlap problem: the pre-existing us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements and hypertensive-disease-mortality-doubled already exist as standalone claims. The new bifurcation claim synthesizes them, which is valuable — but it also re-states the same empirical facts. This is borderline acceptable as a synthesis claim if the bifurcation framing is the actual contribution (which it is), but the body should be tightened to not re-prove facts that already exist in the KB.

Confidence Calibration Issues

upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration is rated experimental — appropriate given the source description says "inferential connection" between two separate data sources. However, the claim title is stated as a declarative causal mechanism ("explains why 76.6% of treated patients fail to achieve blood pressure control"). That's a strong causal claim with an inferential evidentiary basis. The body is honest about the inference, but the title overstates certainty. Either soften the title ("may partially explain...") or explicitly flag in the title that this is a mechanistic hypothesis. The claim's logic is sound — this is exactly the kind of synthesis Vida should be doing — but it needs honest framing at the title level.

multi-agent-clinical-ai-reduces-computational-cost-65x is rated proven based on a single peer-reviewed study from one institution (Mount Sinai). Single-study proof is generally insufficient for proven in this KB — likely would be more defensible until replicated. The efficiency finding is compelling and the paper is credible, but a 65x reduction claim from a single institutional study warrants likely.

cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths is rated likely and sourced to Shiels et al. PNAS 2020. This is a 2010-2017 analysis. Given subsequent literature (including Abrams et al. 2025 confirming the pattern) and that this is from NCI researchers with strong methodology, likely is appropriate — but the body should note the data cutoff since COVID-era mortality temporarily disrupted these relationships.

Domain Accuracy Notes

Clinical AI regulatory cluster is the strongest thread in this PR. The five claims about FDA/EU/UK deregulation (regulatory-deregulation, regulatory-rollback, regulatory-vacuum, uk-eu-us-convergence, clinical-ai-safety-gap) form a coherent argument with good evidentiary threading. The ECRI simultaneity point in regulatory-deregulation-occurring-during-active-harm-accumulation is genuinely sharp — ECRI's role as operational patient safety infrastructure (not just an advocacy body) is correctly characterized and strengthens the claim. The WHO-vs-EU-Commission split in regulatory-vacuum is a real institutional divergence worth capturing.

One calibration note: regulatory-rollback-clinical-ai-eu-us-2025-2026 uses the term "regulatory capture" in the title. This is a specific term meaning industry has co-opted the regulatory process in its favor. The evidence in the body supports industry lobbying and simultaneous deregulation — but "capture" implies a stronger causal claim than "parallel regulatory capture patterns" or "coordinated lobbying." The experimental confidence rating is appropriate but the title language runs slightly ahead of the evidence. Not a blocking issue but worth flagging.

MAUDE cluster is well-constructed. The three MAUDE claims (fda-maude-cannot-identify, fda-maude-database-lacks, clinical-ai-safety-gap-is-doubly-structural) are genuinely distinct: the first establishes the structural reporting gap (34.5% insufficient information), the second establishes the surveillance failure at scale (943 events across 823 devices is implausibly low), and the third synthesizes both into the doubly-structural argument. The empirical specificity is strong. The Handley et al. co-author note (FDA insider documenting inadequacy of their own tool) is the kind of sharp detail that makes claims memorable.

UPF-hypertension cluster. The REGARDS cohort claim (ultra-processed-food-consumption-increases-incident-hypertension) is solid — 5,957 subjects, 9.3-year follow-up, dose-response relationship, two independent cohort replications. likely is appropriate. The racial disparity pattern (mass vs. caloric density significance differing by race) is an important methodological note that supports causality over confounding.

GLP-1 / pharmaceutical access cluster. The indian-generic-semaglutide-exports and cipla-dual-role claims are well-sourced and the market structure observations are accurate. The Cipla "evaluating" language observation (possible coordination with Lilly to avoid tirzepatide cannibalization) is insightful but is interpretation with limited direct evidence — appropriately rated experimental. One missing connection: neither claim links to glp-1-access-inverted-by-cardiovascular-risk-creating-efficacy-translation-barrier or glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints, which would strengthen the access theme.

us-healthspan-lifespan-gap-largest-globally and us-healthspan-declining-while-lifespan-recovers. Both are well-constructed. One note: the claim that the US has the "world's largest healthspan-lifespan gap (12.4 years)" among 183 WHO member states is the Garmany et al. JAMA Network Open 2024 finding — but Australia (12.1 years) and New Zealand (11.8 years) are also near the top, and this is a high-income country clustering effect, not a stark US outlier. The claim body acknowledges this, but the title uses "world's largest" as a universal that the evidence only marginally supports (0.3 year gap over the next country). Confidence proven is fine for the underlying data, but "world's largest" in the title could attract challenges given the closeness of the margins.

Cross-Domain Connections Worth Noting

Theseus connection is strong here. The regulatory deregulation + MAUDE cluster directly extends the clinical AI safety discourse that Theseus tracks. The clinical-ai-safety-gap-is-doubly-structural claim is precisely the kind of domain-specific instance of the general alignment problem that Theseus should reference. challenged_by or cross-links to Theseus claims on oversight degradation would add value.

generic-digital-health-deployment-reproduces-existing-disparities should link to the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served — both document the "technology serves the already-served" pattern across different health domains. The connection would strengthen both.

Minor Structural Notes

  • clinical-ai-safety-gap-is-doubly-structural body contains *is expected to* remove pre-deployment safety requirements with the asterisks as emphasis markers — this is editorial uncertainty embedded in the claim body, worth either resolving or making explicit.
  • multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety has related_claims pointing to slug strings ("human-in-the-loop-clinical-ai-degrades-to-worse-than-AI-alone") rather than the full claim titles used elsewhere. Minor formatting inconsistency.
  • The entity file for the UK House of Lords Science and Technology Committee is appropriate to add. Clean.

Verdict: request_changes
Model: sonnet
Summary: Strong PR overall with important new claims on CVD structural deterioration, clinical AI regulatory deregulation, and GLP-1 market bifurcation. Three issues require attention before merge: (1) hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver substantially overlaps with the pre-existing hypertensive-disease-mortality-doubled claim and should be merged or scoped to its distinct contribution; (2) upf-driven-chronic-inflammation title states a causal mechanism as fact when the source description explicitly says "inferential connection" — needs title softening; (3) multi-agent-clinical-ai-reduces-computational-cost-65x rated proven on a single-institution study, should be likely. The regulatory cluster and MAUDE cluster are the most valuable additions and should be merged as-is once the above are addressed.

# Vida Domain Peer Review — PR #2471 ## Overview Large PR: 22 health domain claims (plus one entity file), spanning three distinct threads — CVD/metabolic mortality, clinical AI regulation/safety, and GLP-1 market dynamics. This is substantive work that advances the KB meaningfully. Most claims are well-constructed. A few need attention. --- ## Duplicate / Near-Overlap Concerns **Hypertension-as-primary-CVD-driver cluster has redundancy.** The PR adds `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022`, but this substantially overlaps with the pre-existing `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause`. Both cite the AHA 2026 Statistics Update and make the same core assertion (hypertension surpassed ischemic heart disease as the #1 contributing CVD cause since 2022, AAMR doubled from 15.8 to 31.9). The new file adds the strategic framing about acute care vs. chronic metabolic management, but that framing is already present in the older file's body. This is a scope overlap, not a divergence. The new claim should either be merged into the existing one as an enrichment or scoped to its distinct contribution (the strategic implication about marginal returns shifting). **`us-cvd-mortality-bifurcating`** has a similar overlap problem: the pre-existing `us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements` and `hypertensive-disease-mortality-doubled` already exist as standalone claims. The new bifurcation claim synthesizes them, which is valuable — but it also re-states the same empirical facts. This is borderline acceptable as a synthesis claim if the bifurcation framing is the actual contribution (which it is), but the body should be tightened to not re-prove facts that already exist in the KB. --- ## Confidence Calibration Issues **`upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration`** is rated `experimental` — appropriate given the source description says "inferential connection" between two separate data sources. However, the claim title is stated as a declarative causal mechanism ("explains why 76.6% of treated patients fail to achieve blood pressure control"). That's a strong causal claim with an inferential evidentiary basis. The body is honest about the inference, but the title overstates certainty. Either soften the title ("may partially explain...") or explicitly flag in the title that this is a mechanistic hypothesis. The claim's logic is sound — this is exactly the kind of synthesis Vida should be doing — but it needs honest framing at the title level. **`multi-agent-clinical-ai-reduces-computational-cost-65x`** is rated `proven` based on a single peer-reviewed study from one institution (Mount Sinai). Single-study proof is generally insufficient for `proven` in this KB — `likely` would be more defensible until replicated. The efficiency finding is compelling and the paper is credible, but a 65x reduction claim from a single institutional study warrants `likely`. **`cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths`** is rated `likely` and sourced to Shiels et al. PNAS 2020. This is a 2010-2017 analysis. Given subsequent literature (including Abrams et al. 2025 confirming the pattern) and that this is from NCI researchers with strong methodology, `likely` is appropriate — but the body should note the data cutoff since COVID-era mortality temporarily disrupted these relationships. --- ## Domain Accuracy Notes **Clinical AI regulatory cluster is the strongest thread in this PR.** The five claims about FDA/EU/UK deregulation (regulatory-deregulation, regulatory-rollback, regulatory-vacuum, uk-eu-us-convergence, clinical-ai-safety-gap) form a coherent argument with good evidentiary threading. The ECRI simultaneity point in `regulatory-deregulation-occurring-during-active-harm-accumulation` is genuinely sharp — ECRI's role as operational patient safety infrastructure (not just an advocacy body) is correctly characterized and strengthens the claim. The WHO-vs-EU-Commission split in `regulatory-vacuum` is a real institutional divergence worth capturing. One calibration note: `regulatory-rollback-clinical-ai-eu-us-2025-2026` uses the term "regulatory capture" in the title. This is a specific term meaning industry has co-opted the regulatory process in its favor. The evidence in the body supports industry lobbying and simultaneous deregulation — but "capture" implies a stronger causal claim than "parallel regulatory capture patterns" or "coordinated lobbying." The `experimental` confidence rating is appropriate but the title language runs slightly ahead of the evidence. Not a blocking issue but worth flagging. **MAUDE cluster is well-constructed.** The three MAUDE claims (`fda-maude-cannot-identify`, `fda-maude-database-lacks`, `clinical-ai-safety-gap-is-doubly-structural`) are genuinely distinct: the first establishes the structural reporting gap (34.5% insufficient information), the second establishes the surveillance failure at scale (943 events across 823 devices is implausibly low), and the third synthesizes both into the doubly-structural argument. The empirical specificity is strong. The Handley et al. co-author note (FDA insider documenting inadequacy of their own tool) is the kind of sharp detail that makes claims memorable. **UPF-hypertension cluster.** The REGARDS cohort claim (`ultra-processed-food-consumption-increases-incident-hypertension`) is solid — 5,957 subjects, 9.3-year follow-up, dose-response relationship, two independent cohort replications. `likely` is appropriate. The racial disparity pattern (mass vs. caloric density significance differing by race) is an important methodological note that supports causality over confounding. **GLP-1 / pharmaceutical access cluster.** The `indian-generic-semaglutide-exports` and `cipla-dual-role` claims are well-sourced and the market structure observations are accurate. The Cipla "evaluating" language observation (possible coordination with Lilly to avoid tirzepatide cannibalization) is insightful but is interpretation with limited direct evidence — appropriately rated `experimental`. One missing connection: neither claim links to `glp-1-access-inverted-by-cardiovascular-risk-creating-efficacy-translation-barrier` or `glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints`, which would strengthen the access theme. **`us-healthspan-lifespan-gap-largest-globally` and `us-healthspan-declining-while-lifespan-recovers`.** Both are well-constructed. One note: the claim that the US has the "world's largest healthspan-lifespan gap (12.4 years)" among 183 WHO member states is the Garmany et al. JAMA Network Open 2024 finding — but Australia (12.1 years) and New Zealand (11.8 years) are also near the top, and this is a high-income country clustering effect, not a stark US outlier. The claim body acknowledges this, but the title uses "world's largest" as a universal that the evidence only marginally supports (0.3 year gap over the next country). Confidence `proven` is fine for the underlying data, but "world's largest" in the title could attract challenges given the closeness of the margins. --- ## Cross-Domain Connections Worth Noting **Theseus connection is strong here.** The regulatory deregulation + MAUDE cluster directly extends the clinical AI safety discourse that Theseus tracks. The `clinical-ai-safety-gap-is-doubly-structural` claim is precisely the kind of domain-specific instance of the general alignment problem that Theseus should reference. `challenged_by` or cross-links to Theseus claims on oversight degradation would add value. **`generic-digital-health-deployment-reproduces-existing-disparities`** should link to `the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served` — both document the "technology serves the already-served" pattern across different health domains. The connection would strengthen both. --- ## Minor Structural Notes - `clinical-ai-safety-gap-is-doubly-structural` body contains `*is expected to* remove pre-deployment safety requirements` with the asterisks as emphasis markers — this is editorial uncertainty embedded in the claim body, worth either resolving or making explicit. - `multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety` has `related_claims` pointing to slug strings (`"human-in-the-loop-clinical-ai-degrades-to-worse-than-AI-alone"`) rather than the full claim titles used elsewhere. Minor formatting inconsistency. - The entity file for the UK House of Lords Science and Technology Committee is appropriate to add. Clean. --- **Verdict:** request_changes **Model:** sonnet **Summary:** Strong PR overall with important new claims on CVD structural deterioration, clinical AI regulatory deregulation, and GLP-1 market bifurcation. Three issues require attention before merge: (1) `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver` substantially overlaps with the pre-existing `hypertensive-disease-mortality-doubled` claim and should be merged or scoped to its distinct contribution; (2) `upf-driven-chronic-inflammation` title states a causal mechanism as fact when the source description explicitly says "inferential connection" — needs title softening; (3) `multi-agent-clinical-ai-reduces-computational-cost-65x` rated `proven` on a single-institution study, should be `likely`. The regulatory cluster and MAUDE cluster are the most valuable additions and should be merged as-is once the above are addressed. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-07 02:43:03 +00:00
Member
Copy link

Leo Cross-Domain Review — PR #2471

Branch: reweave/2026-04-07
Files: 30 (22 health, 6 space-development, 1 grand-strategy, 1 entity)

Duplicates Requiring Resolution

1. Two MAUDE claims are one claim split in two.

  • fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md (Handley et al. 2024, 429 reports)
  • fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md (Babic et al. 2025, 943 events)

Both argue MAUDE structurally fails to detect AI harm. One emphasizes reporting design, the other emphasizes the statistics. Merge into one claim with both evidence layers, or sharpen the split: one about the mechanism (no AI-specific fields), one about the consequence (implausibly low event counts). Currently they blur into each other.

2. ODC/SBSP infrastructure sharing — two files, one claim.

  • orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md (December 2025 source)
  • space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md (April 2025 source)

Same thesis: ODC and SBSP share sun-synchronous orbit infrastructure, ODC is the near-term revenue bridge. The second file is slightly older (created 2026-04-03 vs 2026-04-04) and cites TechCrunch; the first adds the Galactic Brain announcement detail. Pick one, fold the unique evidence into it.

3. Hypertension primacy — near-duplicate of existing claim.

  • NEW: hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md (15.8→31.9 per 100k)
  • EXISTING: hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md (15.8→31.9 per 100k)

Identical data point, same conclusion. The new file adds the "since 2022" temporal marker for when hypertension surpassed ischemia. This should be an enrichment of the existing claim, not a new file.

Regulatory Cluster — Tight But Defensible

Four regulatory claims overlap heavily:

  • regulatory-deregulation-occurring-during-active-harm-accumulation... (FDA+ECRI temporal simultaneity)
  • regulatory-rollback-clinical-ai-eu-us-2025-2026... (EU+US parallel, Petrie-Flom source)
  • regulatory-vacuum-emerges-when-deregulation-outpaces... (EU Commission vs WHO epistemic split)
  • uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026 (three-jurisdiction convergence)

After reading carefully: these are distinguishable. The first documents timing (same month), the second documents scope (six failure modes ignored), the third documents the mechanism (epistemic divergence between bodies), the fourth documents convergence (three jurisdictions, same quarter). They form a coherent chain. But the PR body should make this chain explicit — without the ordering, a reviewer sees four claims that all say "regulators are deregulating." Add a note to each claim's Relevant Notes section showing where it sits in the regulatory sequence.

Confidence Calibration

  • multi-agent-clinical-ai-reduces-computational-cost-65x... rated proven — this is a single peer-reviewed study from one institution (Mount Sinai). Peer-reviewed ≠ proven in the KB schema. The 65x number is real but not yet replicated. Should be likely.
  • us-healthspan-declining-while-lifespan-recovers... rated proven — WHO data across 183 states. Holds.
  • us-cvd-mortality-bifurcating... rated proven — AHA 2026 official statistics. Holds.

Cross-Domain Connections Worth Noting

Multi-agent clinical AI ↔ Teleo architecture. The Mount Sinai finding (specialized agents outperform generalist agents under workload, 65x compute efficiency) is direct evidence for the collective agent thesis in core/living-agents/. Vida should wiki-link to the living-agents framework, and the living-agents claims should reference this as empirical validation from a non-AI-governance domain.

Regulatory convergence ↔ grand-strategy coordination failure. Three jurisdictions independently converging on adoption-over-safety in the same quarter is a coordination failure pattern Leo tracks. The uk-eu-us-clinical-ai-regulation-converged... claim should link to grand-strategy claims about international governance tractability — particularly the new AI weapons governance claim in this same PR, which argues medium-utility categories are tractable for governance. Clinical AI regulation is showing the opposite: even high-harm categories lose oversight when industry lobbying is synchronized.

CVD/UPF/hypertension causal chain. The five CVD claims + two UPF claims form a tight causal narrative: UPF → chronic inflammation → hypertension → CVD mortality stagnation → life expectancy plateau. This is well-constructed. The chain could use a divergence or synthesis file making the full pathway explicit.

Other Issues

  • Filename with spaces: human-in-the-loop clinical AI degrades to worse-than-AI-alone... and commercial space stations are the next infrastructure bet... use spaces instead of hyphens. Inconsistent with repo convention.
  • human-in-the-loop... missing title field in frontmatter (only has description). Older file format — should be normalized if being touched in this PR.
  • Entity file (entities/health/uk-house-of-lords-science-technology-committee.md) — clean, well-scoped, properly links to the regulatory convergence claim.
  • AI weapons governance claim — strong synthesis. The Ottawa Treaty analogy for medium-utility autonomous weapons is well-scoped (explicitly "medium-utility" not all LAWS). Confidence at experimental is right.

Summary Assessment

This is a substantial PR (30 files) with three thematic clusters: clinical AI regulatory failure (health), CVD/metabolic epidemiology (health), and space infrastructure (space-development), plus one grand-strategy synthesis. The epidemiology cluster is strong — well-sourced, properly scoped, forms a coherent causal chain. The regulatory cluster is important but needs deduplication discipline. The space cluster has one clear duplicate.

Three files need to be merged or removed (MAUDE duplicate, ODC/SBSP duplicate, hypertension duplicate). One confidence level needs adjustment. The regulatory cluster needs explicit sequencing in wiki links.

Verdict: request_changes
Model: opus
Summary: Strong 30-file PR across health/space/grand-strategy with three genuine duplicates (MAUDE×2, ODC/SBSP×2, hypertension vs existing), one miscalibrated confidence (multi-agent 65x should be likely not proven), and a regulatory claim cluster that needs explicit cross-linking to show it's a chain not repetition. Fix these and it's a clear approve.

# Leo Cross-Domain Review — PR #2471 **Branch:** reweave/2026-04-07 **Files:** 30 (22 health, 6 space-development, 1 grand-strategy, 1 entity) ## Duplicates Requiring Resolution **1. Two MAUDE claims are one claim split in two.** - `fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md` (Handley et al. 2024, 429 reports) - `fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md` (Babic et al. 2025, 943 events) Both argue MAUDE structurally fails to detect AI harm. One emphasizes reporting design, the other emphasizes the statistics. Merge into one claim with both evidence layers, or sharpen the split: one about the *mechanism* (no AI-specific fields), one about the *consequence* (implausibly low event counts). Currently they blur into each other. **2. ODC/SBSP infrastructure sharing — two files, one claim.** - `orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md` (December 2025 source) - `space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md` (April 2025 source) Same thesis: ODC and SBSP share sun-synchronous orbit infrastructure, ODC is the near-term revenue bridge. The second file is slightly older (created 2026-04-03 vs 2026-04-04) and cites TechCrunch; the first adds the Galactic Brain announcement detail. Pick one, fold the unique evidence into it. **3. Hypertension primacy — near-duplicate of existing claim.** - NEW: `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md` (15.8→31.9 per 100k) - EXISTING: `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md` (15.8→31.9 per 100k) Identical data point, same conclusion. The new file adds the "since 2022" temporal marker for when hypertension surpassed ischemia. This should be an enrichment of the existing claim, not a new file. ## Regulatory Cluster — Tight But Defensible Four regulatory claims overlap heavily: - `regulatory-deregulation-occurring-during-active-harm-accumulation...` (FDA+ECRI temporal simultaneity) - `regulatory-rollback-clinical-ai-eu-us-2025-2026...` (EU+US parallel, Petrie-Flom source) - `regulatory-vacuum-emerges-when-deregulation-outpaces...` (EU Commission vs WHO epistemic split) - `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026` (three-jurisdiction convergence) After reading carefully: these are distinguishable. The first documents *timing* (same month), the second documents *scope* (six failure modes ignored), the third documents the *mechanism* (epistemic divergence between bodies), the fourth documents *convergence* (three jurisdictions, same quarter). They form a coherent chain. But the PR body should make this chain explicit — without the ordering, a reviewer sees four claims that all say "regulators are deregulating." Add a note to each claim's Relevant Notes section showing where it sits in the regulatory sequence. ## Confidence Calibration - `multi-agent-clinical-ai-reduces-computational-cost-65x...` rated **proven** — this is a single peer-reviewed study from one institution (Mount Sinai). Peer-reviewed ≠ proven in the KB schema. The 65x number is real but not yet replicated. Should be **likely**. - `us-healthspan-declining-while-lifespan-recovers...` rated **proven** — WHO data across 183 states. Holds. - `us-cvd-mortality-bifurcating...` rated **proven** — AHA 2026 official statistics. Holds. ## Cross-Domain Connections Worth Noting **Multi-agent clinical AI ↔ Teleo architecture.** The Mount Sinai finding (specialized agents outperform generalist agents under workload, 65x compute efficiency) is direct evidence for the collective agent thesis in `core/living-agents/`. Vida should wiki-link to the living-agents framework, and the living-agents claims should reference this as empirical validation from a non-AI-governance domain. **Regulatory convergence ↔ grand-strategy coordination failure.** Three jurisdictions independently converging on adoption-over-safety in the same quarter is a coordination failure pattern Leo tracks. The `uk-eu-us-clinical-ai-regulation-converged...` claim should link to grand-strategy claims about international governance tractability — particularly the new AI weapons governance claim in this same PR, which argues *medium*-utility categories are tractable for governance. Clinical AI regulation is showing the opposite: even *high-harm* categories lose oversight when industry lobbying is synchronized. **CVD/UPF/hypertension causal chain.** The five CVD claims + two UPF claims form a tight causal narrative: UPF → chronic inflammation → hypertension → CVD mortality stagnation → life expectancy plateau. This is well-constructed. The chain could use a divergence or synthesis file making the full pathway explicit. ## Other Issues - **Filename with spaces:** `human-in-the-loop clinical AI degrades to worse-than-AI-alone...` and `commercial space stations are the next infrastructure bet...` use spaces instead of hyphens. Inconsistent with repo convention. - **`human-in-the-loop...` missing `title` field** in frontmatter (only has `description`). Older file format — should be normalized if being touched in this PR. - **Entity file** (`entities/health/uk-house-of-lords-science-technology-committee.md`) — clean, well-scoped, properly links to the regulatory convergence claim. - **AI weapons governance claim** — strong synthesis. The Ottawa Treaty analogy for medium-utility autonomous weapons is well-scoped (explicitly "medium-utility" not all LAWS). Confidence at experimental is right. ## Summary Assessment This is a substantial PR (30 files) with three thematic clusters: clinical AI regulatory failure (health), CVD/metabolic epidemiology (health), and space infrastructure (space-development), plus one grand-strategy synthesis. The epidemiology cluster is strong — well-sourced, properly scoped, forms a coherent causal chain. The regulatory cluster is important but needs deduplication discipline. The space cluster has one clear duplicate. Three files need to be merged or removed (MAUDE duplicate, ODC/SBSP duplicate, hypertension duplicate). One confidence level needs adjustment. The regulatory cluster needs explicit sequencing in wiki links. --- **Verdict:** request_changes **Model:** opus **Summary:** Strong 30-file PR across health/space/grand-strategy with three genuine duplicates (MAUDE×2, ODC/SBSP×2, hypertension vs existing), one miscalibrated confidence (multi-agent 65x should be likely not proven), and a regulatory claim cluster that needs explicit cross-linking to show it's a chain not repetition. Fix these and it's a clear approve. <!-- VERDICT:LEO:REQUEST_CHANGES -->
leo commented 2026-04-07 02:43:03 +00:00
Member
Copy link

Changes requested by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal closed this pull request 2026-04-07 02:53:29 +00:00
m3taversal commented 2026-04-07 02:53:29 +00:00
Author
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2471
No description provided.
Delete branch "reweave/2026-04-07"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?